Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -4.76 is 33% below its 5-year average of -3.57, near the low end of its 5-year range (-8.36–4.97).
11.93% above its 12-month average of -5.40.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.94.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 32 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-02T19:55:24.331Z. Historical observations retain their original dates. Historical series through 2022-08-08.
EARNINGS PER SHARE (EPS)
-4.76
EARNINGS PER SHARE (EPS) AVG TTM
-5.40
EARNINGS PER SHARE (EPS) AVG 3Y
-5.28
EARNINGS PER SHARE (EPS) AVG 5Y
-3.57
EARNINGS PER SHARE (EPS) AVG 10Y
-2.56
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+11.93%
CURRENT VS 3Y AVG
+9.81%
CURRENT VS 5Y AVG
-33.27%
CURRENT VS 10Y AVG
-86.20%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CRISPR Therapeutics AG
Market Cap
$5.33B
Earnings Per Share (EPS)
-4.76
TTM Avg
-5.40
3Y Avg
-5.28
5Y Avg
-3.57
Market Cap
$5.21B
Earnings Per Share (EPS)
0.85
TTM Avg
1.12
3Y Avg
0.90
5Y Avg
0.76
Market Cap
$5.10B
Earnings Per Share (EPS)
2.42
TTM Avg
2.12
3Y Avg
1.80
5Y Avg
1.31
Market Cap
$5.60B
Earnings Per Share (EPS)
-3.31
TTM Avg
-2.88
3Y Avg
-2.49
5Y Avg
-2.72
Market Cap
$6.45B
Earnings Per Share (EPS)
-0.63
TTM Avg
0.57
3Y Avg
0.18
5Y Avg
-0.06
Market Cap
$6.64B
Earnings Per Share (EPS)
19.92
TTM Avg
19.26
3Y Avg
18.34
5Y Avg
18.42
Market Cap
$2.74B
Earnings Per Share (EPS)
3.86
TTM Avg
3.33
3Y Avg
1.17
5Y Avg
0.32
Market Cap
$8.03B
Earnings Per Share (EPS)
1.40
TTM Avg
-0.79
3Y Avg
-1.41
5Y Avg
-1.76
Market Cap
$2.52B
Earnings Per Share (EPS)
-0.86
TTM Avg
-2.70
3Y Avg
-2.81
5Y Avg
-3.40
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | $5.33B | -4.76 | -5.40 | -5.28 | -3.57 |
| Doximity, Inc. (DOCS)vs › | $5.21B | 0.85 | 1.12 | 0.90 | 0.76 |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 2.42 | 2.12 | 1.80 | 1.31 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.60B | -3.31 | -2.88 | -2.49 | -2.72 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.45B | -0.63 | 0.57 | 0.18 | -0.06 |
| Chemed Corporation (CHE)vs › | $6.64B | 19.92 | 19.26 | 18.34 | 18.42 |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 3.86 | 3.33 | 1.17 | 0.32 |
| Oscar Health, Inc. (OSCR)vs › | $8.03B | 1.40 | -0.79 | -1.41 | -1.76 |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | -0.86 | -2.70 | -2.81 | -3.40 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.14B | -1.04 | -1.56 | -1.52 | -1.27 |
Trailing EPS (TTM)
$-4.76
Forward EPS (Est.)
$-4.38
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -6.47 |
| 2024-12-31 | -4.34 |
| 2023-12-31 | -1.94 |
| 2022-12-31 | -8.36 |
| 2021-12-31 | 4.97 |
| 2020-12-31 | -5.29 |
| 2019-12-31 | 1.23 |
| 2018-12-31 | -3.44 |
| 2017-12-31 | -1.71 |
| 2016-12-31 | -1.89 |
| 2015-12-31 | -0.88 |
| 2014-12-31 | -0.23 |
